A diversified healthcare business against a pure-play pharmaceutical one rebuilding its pipeline.
JNJ and PFE are both large-cap healthcare names with substantial dividends, but they carry very different risk. Johnson & Johnson spreads its exposure across pharmaceuticals and medical devices, where revenue follows procedure volumes rather than patents. Pfizer is a pure pharmaceutical business that has been through an extreme revenue cycle and is now buying and building its way to the next one. The comparison is mostly about pipeline dependence and how much diversification you want inside a single healthcare position.
Pharmaceuticals and medical technology, following the separation of the consumer health business.
A pure pharmaceutical company rebuilding its pipeline through acquisitions after an extraordinary pandemic revenue cycle.
For pharmaceutical businesses, research spending is the pipeline. Sustained under-investment shows up as a revenue problem several years later.
Disclosed in the filings and decisive here: how much revenue loses exclusivity within five years determines what has to be replaced.
Both are held largely for income. Payout against free cash flow shows whether the dividend depends on products that are about to lose protection.
Devices and pharmaceuticals grow for entirely different reasons. Segment detail is the only way to see which engine is actually working.
A high healthcare yield often reflects a market discounting future patent expiries. Check what proportion of revenue faces exclusivity loss before treating a yield gap as an opportunity.
Device revenue follows procedure volumes and rarely falls off a cliff; drug revenue can drop sharply on one patent expiry or trial failure. That is the core structural difference between these two.
Educational only. Not investment advice.
A free account charts one company on one metric over the last five years. Putting companies against each other — up to five, on up to four metrics, over their whole history — is part of Ultimate, and every new account gets it for seven days: create an account, confirm your email, and the trial starts without a card. A chart is an address, so the link you made keeps working the day you subscribe.
Type up to five tickers onto one canvas — any listed names, not just the pairs on this site. Each company keeps its own colour on every chart.
Choose up to four metrics. Two share one chart with an axis each; more split into a panel per metric. Statement figures sit on each company’s own fiscal dates, so a quarter is never stretched to look like a day.
Open a company’s page for its Quality Score, its intrinsic value and its fair value, save it to a watchlist, or export the chart as an image. The whole chart lives in its link, so it can be bookmarked or sent.
Yield alone does not answer it. Compare the dividend against free cash flow rather than earnings, and check how much revenue faces loss of exclusivity in the next few years — that is what determines whether the cash flow behind it persists.
Johnson & Johnson, because MedTech revenue is driven by procedure volumes rather than patents and does not face the same cliffs. Pfizer is a pure pharmaceutical business, so pipeline outcomes matter more to it.
It is the sharp revenue drop when a drug loses exclusivity and generics enter. For pharmaceutical companies it is the single largest predictable risk, which is why comparing exposure over the next five years matters more than comparing current growth.
Comparing companies is part of Ultimate · 7-day free trial included · No credit card to start